Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma

NCT01208454 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01208454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01208454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2010
Completion date
Not reported
Enrollment
29 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

localized unresectable neuroblastoma, recurrent neuroblastoma, regional neuroblastoma, stage 4 neuroblastoma, stage 4s neuroblastoma